US20060193927A1 - Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions - Google Patents

Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions Download PDF

Info

Publication number
US20060193927A1
US20060193927A1 US10563980 US56398004A US2006193927A1 US 20060193927 A1 US20060193927 A1 US 20060193927A1 US 10563980 US10563980 US 10563980 US 56398004 A US56398004 A US 56398004A US 2006193927 A1 US2006193927 A1 US 2006193927A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
icarin
extracts
ipomea
sexual
purified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10563980
Inventor
Ezio Bombardelli
Original Assignee
Ezio Bombardelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/39Convolvulaceae (Morning-glory family), e.g. bindweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender

Abstract

This invention relates to combinations of vasoactive substances which are useful in the treatment of sexual dysfunctions associated with poor local blood supply and/or insufficient lubrication. The active compounds are selected from a:—esculoside or visnadine;—forskolin or extracts containing it, or alternatively, purified lipophilic extracts of plants of the genus Ipomea;—esters of ximenynic acid;—optionally, at least one compound selected from a icarin or derivatives or extracts thereof which contain it, amentoflavone, and Gingko biloba dimeric flavones. The combination of these vasoactive substances is incorporated in gels and lotions designed to be applied to the genital organs. These formulations are useful in inducing erection of the male and female sex organs and enhancing orgasm and sexual performance. The formulations are particularly useful in the treatment of female sexual dysfunctions.

Description

  • [0001]
    This invention relates to combinations of vasoactive substances which are useful in the treatment of sexual dysfunctions associated with poor local blood supply and/or insufficient lubrication.
  • [0002]
    Loss of erectile capacity in men is an event which adversely affects the physical, emotional and social sphere of the sufferer. When this sexual dysfunction arises, men come to expect yet another “failure” whenever they have sexual intercourse, thus generating a particular state of mind which is both cause and effect of a problem that was originally only physical.
  • [0003]
    As sexuality is an important means of communication between a couple, deterioration of erectile potency leads to a build-up of emotional tension between the two partners and a consequent deterioration in their relationship. Loss or absence of erectile capacity and lubrication to various extents also constitutes a serious problem in women, with adverse consequences on the couple's relationship. A variety of mediators and receptors are involved in the tumescence of the male and female genital organs. Acetylcholine (Ach), for example, is the best-known parasympathetic neurotransmitter. In vitro, it causes relaxation of smooth muscle striations previously contracted by noradrenaline, and contraction of smooth muscle cell isolates. This suggests that the main action of Ach is to contract the smooth muscles and determine the release of a substance which causes cavernous relaxation. In addition to Ach, the parasympathetic nerves also release other neurotransmitters, including nitric oxide (NO), VIP and CGRP (calcitonin gene-related peptide).
  • [0004]
    Nitric oxide (NO) is synthesised from L-Arginine through the action of the enzyme NOs (nitric oxide synthetase). The two sources of NO in the penis and clitoris are represented by the parasympathetic nerve endings and the endothelium, synthesised by different NOs enzymes: nNOs (neuronal NOs), which is present in the cytoplasm of the parasympathetic nerves, and eNOs (endothelial NOs), found in the endothelium of the blood vessels and trabecular tissue, which mainly seems to bond to the cell membranes. Numerous experiments have demonstrated that stimulation of the parasympathetic nerves leads to the release of NO as a result of direct action by the nerve endings (reaction catalysed by nNOs) and indirect action resulting from the effect of Ach, released by the parasympathetic nerves, on the vascular endothelium, with stimulation of eNos. There is also evidence in support of a tonic release of NO by the endothelium and the involvement of partial oxygen pressure. In fact, periods when partial oxygen tension is low, as in conditions of flaccidity, are associated with reduced NOs activity. Finally, various studies have confirmed the ability of other substances, whose physiological significance has not yet been established, to determine the release of NO by the endothelium. The clinical evidence that NO plays a part in the erection of the penis includes the observation that intracavernous injection of NO-releasing substances can produce an erection in impotent men as well as men with normal sexual potency.
  • [0005]
    The Ach released by the parasympathetic fibres bonds to muscarinic receptors present on the endothelial cell membranes and the smooth muscle cell membranes. In the endothelium, this bond promotes the activation of eNOs with subsequent release of NO and inhibition of noradrenaline (NA). Inhibition of NA release is essential to the physiology of the erection. NA, released by the sympathetic nerve endings, bonds with α1-adrenergic membrane receptors (in the cavernous tissue, type α receptors outnumber type β receptors by a ratio of 10:1), leading to an increase in the activity of phospholipase C (PLC), which converts phosphatidylinositol (PIP) into inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 induces the release of calcium ions from the sarcoplasmic reticulum, and DAG stimulates the enzyme protein kinase C (PKC). This enzyme, by opening the L-type calcium channels and closing the potassium channels, increases the intracytoplasmic calcium concentration, leading to contraction of the smooth muscles.
  • [0006]
    The NO released by the parasympathetic nerve endings and the endothelium is a lipophilic molecule, and therefore able to cross the smooth muscle cell membrane.
  • [0007]
    Despite its short half-life (approx. 5 seconds), after reaching the cytoplasm of the muscle cell it stimulates its receptor, the enzyme guanylate cyclase, to convert guanosine triphosphate (GTP) into the second active messenger, cyclic guanosine monophosphate (cGMP). The intracytoplasmic levels of cGMP are controlled by the extent of the nitrergic stimulus and the catabolism rate of the enzyme phosphodiesterase V (PDE). Once stimulated, cGMP activates the enzyme protein kinase G (PKG), which closes the L-type calcium channels and opens the potassium channels. VIP, like the prostanoids (PGE1), mainly acts via specific receptors on the surface of the smooth muscle cell, stimulating the enzyme adenylate cyclase (a membrane enzyme). This enzyme converts ATP into cyclic AMP (cAMP), which in turn causes a reduction in the intracellular calcium concentration and relaxation of the smooth muscles.
  • [0008]
    It has now been discovered that by associating esculoside or visnadine, icarin and derivatives or extracts which contain it, amentoflavone, dimers of Gingko biloba, forskolin or purified extracts of Coleus forskolii, purified extracts of plants of the genus Ipomea and esters of ximenynic acid, which modify physiologically dulled or altered parameters, and exploiting the synergic interactions between the active constituents, the functionality of the genital organs can be restored very effectively.
  • [0009]
    This invention relates in particular to combinations of vasoactive substances useful in the treatment of sexual dysfunctions associated with poor local blood supply to the male and female sex organs.
  • [0010]
    The topical compositions according to the invention contain:
      • esculoside or visnadine;
      • forskolin or extracts containing it, or alternatively, purified lipophilic extracts of plants of the genus Ipomea;
      • esters of ximenynic acid;
      • optionally, at least one compound selected from a icarin or derivatives or extracts thereof which contain it, amentoflavone, and Gingko biloba dimeric flavones.
  • [0015]
    Visnadine is a coumarin mainly found in the seeds of Ammi visnaga, a plant traditionally used to treat anginoid disorders. The compound has recently been used in the pharmaceutical field as a coronary dilator. We have demonstrated on various occasions that this compound, when applied topically, has a strong vasokinetic action on the precapillary arteries and arterioles, increasing the blood flow and tissue perfusion (EP 0418806). The supply of arterial blood to the erectile tissues induces the start of the erection and maintains it for as long as the compound is present in the tissues. Visnadine also has an anti-phosphodiesterase activity useful to maintain the cyclic nucleotides.
  • [0016]
    Esculoside, a coumarin glucoside present in many plants, such as Aesculus hippocastanum, Fraxinus communis, etc., possesses a vasokinetic action and venotropic activity at both venous and arterial levels.
  • [0017]
    Icarin and its derivatives act on cGMP phosphodiesterase V. High levels of cGMP are required to maintain the erection in the male and female genital organs and therefore the performance necessary for sexual intercourse. Icarin derivatives include 7-hydroxyethyl-icarin or 7-aminoethyl-icarin, 7-hydroxyethyl-3-0-ramnosyl-icarin, 7-aminoethyl-7-desgluco-3-ramnosyl-icarin, 8-dihydro-icarin and its glucosides in 7 and 3, and 7-hydroxyethyl-7-desgluco-icarin.
  • [0018]
    Amentoflavone is a biflavone present in modest amounts in numerous plants, such as Gingko biloba, Brakeringea zanguebarica and Taxus sp. The addition of amentoflavone is particularly useful in some formulations, and is one of the subjects of this invention, because it acts as a very powerful inhibitor of phosphodiesterase and on the release of oxytocin, which is a known aphrodisiac at low doses.
  • [0019]
    Forskolin, and the extracts which contain it, is a known adenylate cyclase agonist. A purified extract of Coleus forskolii is particularly preferred.
  • [0020]
    Extracts of plants of the genus Ipomea also possess a significant activity on adenylate cyclase; the standardised lipophilic extracts of Ipomea hederacea, Ipomea parassitica and Ipomea batatas are particularly preferred.
  • [0021]
    The formulations according to the invention improve sexual performance, especially in women. For example, a combination in gel form containing 1% esculoside, 0.2% forskolin and 1% ethyl ximenynate was administered to a group of 10 female volunteers of child-bearing age. The efficacy test, in which the blood flow parameters in the external genital organs were instrumentally measured by a non-invasive method (Laser Doppler and optical probe videocapillaroscopy), demonstrated that the blood flow increased by up to 200% of the basal value; as regards subjective sensations, the patients reported general well-being, and sexual excitement within half an hour. In men, application of the formulations according to the invention leads to a rapid erection which is prolonged for as long as required to complete the act of sexual intercourse.
  • [0022]
    The following examples illustrate the invention.
  • EXAMPLE 1
  • [0023]
    Esculoside 1.00 g
    Ethyl ximeninate 2.00 g
    Coleus purified extract >80% 0.20 g
    Polyethylene 400 10.00 g
    Ethoxydiglycol (Transcutol - Gattefossé) 10.00 g
    Caprylic/Capric PEG-6 glycerides 10.00 g
    (Softigen 767 - Huls)
    Sorbitol 10.00 g
    Polysorbate 20 8.00 g
    Carbomer (Ultrez 10 - B F Goodrich) 1.00 g
    Imidazolidinyl urea 0.30 g
    Xanthane gum (Keltrol TF - Kelco) 0.30 g
    Methyl paraben 0.20 g
    Disodium EDTA 0.10 g
    Hydroxytoluene butoxide 0.05 g
    10% sol. sodium hydroxide 2.00 g
    Perfume (Jenny - Dragoco) 0.01 g
    Water q.s. to 100 g
  • EXAMPLE 2
  • [0024]
    Visnadine 1.00 g
    Ethyl ximeninate 2.00 g
    Coleus purified extract >80% 0.20 g
    polyethylene 400 10.00 g
    Ethoxydiglycol (Transcutol - Gattefossé) 10.00 g
    Caprylic/Capric PEG-6 glycerides 10.00 g
    (Softigen 767 - Huls)
    Sorbitol 10.00 g
    Polysorbate 20 8.00 g
    Carbomer (Ultrez 10 - B F Goodrich) 1.00 g
    Imidazolidinyl urea 0.30 g
    Xanthane gum (Keltrol TF - Kelco) 0.30 g
    Methyl paraben 0.20 g
    Disodium EDTA 0.10 g
    Hydroxytoluene butoxide 0.05 g
    10% sol. sodium hydroxide 2.00 g
    Perfume (Jenny - Dragoco) 0.01 g
    Water q.s. to 100 g
  • EXAMPLE 3
  • [0025]
    Visnadine 1.00 g
    7-hydroxyethyl-7-desgluco-icarin 1.00 g
    Forskolin 0.20 g
    Amentoflavone 0.20 g
    Ethyl ximeninate 2.00 g
    Polyethylene 400 10.00 g
    Ethoxydiglycol (Transcutol - Gattefossé) 10.00 g
    Caprylic/Capric PEG-6 glycerides 10.00 g
    (Softigen 767 - Huls)
    Sorbitol 10.00 g
    Polysorbate 20 8.00 g
    Carbomer (Ultrez 10 - B F Goodrich) 1.00 g
    Imidazolidinyl urea 0.30 g
    Xanthane gum (Keltrol TF - Kelco) 0.30 g
    Methyl paraben 0.20 g
    Disodium EDTA 0.10 g
    Hydroxytoluene butoxide 0.05 g
    10% sol. sodium hydroxide 2.00 g
    Perfume (Jenny - Dragoco) 0.01 g
    Water q.s. to 100 g
  • EXAMPLE 4
  • [0026]
    Esculoside 1.00 g
    7-Hydroxyethyl-7desgluco-icarin 1.00 g
    Ipomea hederacea lyophilic standardized extract 0.20 g
    Gingko biloba dimeric flavones 0.20 g
    Ethyl ximeninate 1.00 g
    Polyethylene 400 10.00 g
    Ethoxydiglycol (Transcutol - Gattefossé) 10.00 g
    Caprylic/Capric PEG-6 glycerides 10.00 g
    (Softigen 767 - Huls)
    Sorbitol 10.00 g
    Polysorbate 20 8.00 g
    Carbomer (Ultrez 10 - B F Goodrich) 1.00 g
    Imidazolidinyl urea 0.30 g
    Xanthane gum (Keltrol TF - Kelco) 0.30 g
    Methyl paraben 0.20 g
    Disodium EDTA 0.10 g
    Hydroxytoluene butoxide 0.05 g
    10% Sol. sodium hydroxide 2.00 g
    Perfume (Jenny - Dragoco) 0.01 g
    Water q.s. to 100 g

Claims (9)

  1. 1. Topical compositions containing:
    esculoside or visnadine;
    forskolin or extracts containing it, or alternatively, purified lip ophilic extracts of plants of the genus Ipomea;
    esters of ximenynic acid;
    optionally, at least one compound selected from icarin or derivatives or extracts thereof which contain it, amentoflavone, and Gingko biloba dimeric flavones.
  2. 2. Compositions as claimed in claim 1, wherein icarin derivatives comprise 7-hydroxyethyl-7-desgluco-icarin, 7-hydroxyethyl-icarin, 7-aminoethyl-icarin, 7-hydroxyethyl-3-0-rhamnosyl-icarin, 7-amino ethyl-3-rhamnosyl-icarin, 8-dihydro-icarin or its glycosides in 7 and 3.
  3. 3. Compositions as claimed in claim 1, wherein Gingko biloba dimeric flavones comprise amentoflavone.
  4. 4. Compositions as claimed in claim 1, wherein the ximenynic acid ester is the ethyl ester.
  5. 5. Compositions as claimed in claim 1 containing Visnadine, Coleus forskolii purified extract, ximenynic acid ethyl ester, lubricants and anti-irritant excipients.
  6. 6. Compositions as claimed in claim 1 containing esculoside, Coleus forskolii purified extract, ximenynic acid ethyl ester.
  7. 7. Compositions as claimed in claim 1 containing Visnadine, Forskolin e ethyl ximenynate.
  8. 8. Compositions as claimed in claim 1 wherein the purified extracts of Ipomea plants are selected from Ipomea hederacea, Ipomea parassitica, Ipomea batatas.
  9. 9. The use of a combination of:
    esculoside or visnadine;
    forskolin or extracts containing it, or alternatively, purified lipophilic extracts of plants of the genus Ipomea;
    esters of ximenynic acid;
    optionally, at least one compound selected from a icarin or derivatives or extracts thereof which contain it, amentoflavone, and Gingko biloba dimeric flavones;
    for the preparation of compositions for the topical treatment of sexual dysfunctions.
US10563980 2003-07-11 2004-07-06 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions Abandoned US20060193927A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITMI20031428 2003-07-11
ITMI2003A001428 2003-07-11
PCT/EP2004/007374 WO2005004890A1 (en) 2003-07-11 2004-07-06 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12496194 US8092844B2 (en) 2003-07-11 2009-07-01 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions
US13240016 US8287926B2 (en) 2003-07-11 2011-09-22 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions

Publications (1)

Publication Number Publication Date
US20060193927A1 true true US20060193927A1 (en) 2006-08-31

Family

ID=34044550

Family Applications (3)

Application Number Title Priority Date Filing Date
US10563980 Abandoned US20060193927A1 (en) 2003-07-11 2004-07-06 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions
US12496194 Active US8092844B2 (en) 2003-07-11 2009-07-01 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions
US13240016 Active US8287926B2 (en) 2003-07-11 2011-09-22 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12496194 Active US8092844B2 (en) 2003-07-11 2009-07-01 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions
US13240016 Active US8287926B2 (en) 2003-07-11 2011-09-22 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions

Country Status (11)

Country Link
US (3) US20060193927A1 (en)
EP (2) EP1644014B1 (en)
JP (1) JP4892342B2 (en)
KR (1) KR101146867B1 (en)
CN (1) CN1822848B (en)
CA (1) CA2532825C (en)
DE (2) DE602004023137D1 (en)
DK (2) DK1644014T3 (en)
ES (2) ES2286658T3 (en)
RU (2) RU2356568C2 (en)
WO (1) WO2005004890A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006021192D1 (en) * 2005-03-12 2011-05-19 Unilever Nv Visnadine for the treatment of scalp itching
EP2011496A1 (en) * 2007-07-03 2009-01-07 Indena S.P.A. Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions
CN101606928B (en) 2008-06-18 2011-12-07 河南大学 Use of a compound in the manufacture of ear Huashan Biflavones aspect hypolipidemic agents
WO2015099521A3 (en) 2013-12-24 2015-09-11 Biotropics Malaysia Bhd Fruit extracts and extract formulations of canarium odontophyllum as actives and related invention embodiments
WO2018031216A1 (en) * 2016-08-12 2018-02-15 Steven Rothman Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376371A (en) * 1989-10-27 1994-12-27 Indena S.P.A. Compositions for treating fat deposits in humans

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304603B1 (en) 1987-07-27 1992-10-21 INDENA S.p.A. Polyunsaturated acids having vasokinetic action and pharmaceutical and cosmetic formulations containing them
EP0418806B1 (en) * 1989-09-21 1994-01-05 INDENA S.p.A. Pharmaceutical compositions havin activity on the cutaneous microcirculation
DE69526882T2 (en) * 1994-07-12 2003-01-02 Indena Spa Esculosid containing preparations and their use in cosmetics and pharmacy
US5665335A (en) * 1994-07-19 1997-09-09 Indena S.A. Combinations of vasoactive substances with fatty acids to prevent hair loss
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
JPH09157136A (en) 1995-12-08 1997-06-17 Lion Corp Hair restorer/hair tonic
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc Treatment of female sexual dysfunction
CA2340206A1 (en) 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
US20020013280A1 (en) * 2000-06-16 2002-01-31 Zhongcheng Xin Pharmaceutical composition for preventing and treating sexual dysfunction and vasculargenic disease comprising icariin
DE60130007D1 (en) * 2000-06-27 2007-09-27 Qualilife Pharmaceuticals Inc Compositions and methods for treating female sexual response
DK1392335T3 (en) * 2001-06-05 2007-09-17 Indena Spa A pharmaceutical and / or cosmetic composition for the treatment of localized adiposities and cellulite

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376371A (en) * 1989-10-27 1994-12-27 Indena S.P.A. Compositions for treating fat deposits in humans

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness

Also Published As

Publication number Publication date Type
EP1644014A1 (en) 2006-04-12 application
US8092844B2 (en) 2012-01-10 grant
US8287926B2 (en) 2012-10-16 grant
RU2006100305A (en) 2006-06-10 application
ES2330795T3 (en) 2009-12-15 grant
ES2286658T3 (en) 2007-12-01 grant
DE602004023137D1 (en) 2009-10-22 grant
DK1797876T3 (en) 2009-12-21 grant
US20090269426A1 (en) 2009-10-29 application
RU2008148461A (en) 2010-06-20 application
WO2005004890A1 (en) 2005-01-20 application
CN1822848A (en) 2006-08-23 application
CA2532825C (en) 2013-12-10 grant
CN1822848B (en) 2010-05-26 grant
DE602004006271T2 (en) 2008-01-10 grant
EP1644014B1 (en) 2007-05-02 grant
KR101146867B1 (en) 2012-05-16 grant
JP4892342B2 (en) 2012-03-07 grant
JP2009513518A (en) 2009-04-02 application
EP1797876A1 (en) 2007-06-20 application
EP1797876B1 (en) 2009-09-09 grant
DK1644014T3 (en) 2007-09-10 grant
KR20060028746A (en) 2006-03-31 application
CA2532825A1 (en) 2005-01-20 application
US20120009283A1 (en) 2012-01-12 application
RU2356568C2 (en) 2009-05-27 grant
DE602004006271D1 (en) 2007-06-14 grant
RU2480229C2 (en) 2013-04-27 grant

Similar Documents

Publication Publication Date Title
Klerman et al. Clinical experience with dihydroxyphenylalanine (DOPA) in depression
Berger et al. The cholinergic rapid eye movement sleep induction test with RS-86: State or trait marker of depression?
Secades et al. Citicoline-Pharmacological and Clinical Review, 2006 Update
Kruk Neurotransmitters and drugs
US6080410A (en) Method for reducing daily stress and anxiety in adults
US5731339A (en) Methods and formulations for modulating the human sexual response
US6544563B2 (en) Method and composition for improving sexual fitness
Luke Mechanism of cyclosporine-induced hypertension
Ramelet et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution
Bailey et al. Acute mountain sickness; prophylactic benefits of antioxidant vitamin supplementation at high altitude
Diamond et al. Ginkgo biloba extract: mechanisms and clinical indications
Khayyal et al. Blood pressure lowering effect of an olive leaf extract (Olea europaea) in L-NAME induced hypertension in rats
Machado et al. Antidepressant-like effect of rutin isolated from the ethanolic extract from Schinus molle L. in mice: evidence for the involvement of the serotonergic and noradrenergic systems
US20070036742A1 (en) Methods and compositions for modulating hair growth or regrowth
Bilia et al. Kava-kava and anxiety: growing knowledge about the efficacy and safety
Salahdeen et al. Effect of aqueous leaf extract of Tridax procumbens on blood pressure and heart rate in rats
Secades Citicoline: pharmacological and clinical review, 2010 update
US20030157185A1 (en) Topical treatment of neuropathy
ZAUNER et al. The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review
Tam et al. Yohimbine: a clinical review
Sears Regulation of aqueous flow by the adenylate cyclase receptor complex in the ciliary epithelium
Karst et al. Acupuncture in the treatment of alcohol withdrawal symptoms: a randomized, placebo‐controlled inpatient study
Choi et al. In vitro and in vivo experimental effect of Korean red ginseng on erection
Melloni et al. Melloni's illustrated medical dictionary
EP0692250A2 (en) Formulations containing esculoside and the use thereof in the pharmaceutical and cosmetic fields